| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
The compound has shown potential immunosuppressive properties in research studies. It has been demonstrated to inhibit the proliferation of human lymphocytes in response to lipopolysaccharides (LPS). Additionally, it suppresses the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα. These effects suggest that the compound or its derivatives may interact with immune cell signaling pathways, potentially involving Toll-like receptors or other inflammatory mediators. However, the compound is primarily used as a building block in peptide synthesis, and its immunosuppressive properties are observed in the context of synthetic peptide research rather than as a direct drug target.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies on this N-methylated aspartic acid derivative have demonstrated its ability to inhibit the proliferation of human lymphocytes in response to lipopolysaccharides (LPS). It also suppresses the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα. These activities suggest potential immunomodulatory properties for peptides incorporating this building block. As an aspartic acid derivative, this compound may be used in cell-based assays to investigate amino acid transport, peptide stability, and the effects of N-methylation on peptide biological activity. The compound can also be utilized in studies examining the role of aspartic acid in peptide conformation and function. |
| ln Vivo |
In vivo studies on this compound are limited as it is primarily used as a building block in peptide synthesis rather than as a therapeutic agent. The immunosuppressive properties observed in vitro suggest that peptides incorporating this building block may have potential in modulating immune responses in vivo. However, specific in vivo pharmacological data for this exact compound remains limited. As a protected amino acid, it may be administered in animal studies to evaluate the pharmacokinetics and bioavailability of N-methylated aspartic acid derivatives. All animal studies must comply with institutional ethical guidelines.
|
| Enzyme Assay |
Non-cell-based enzyme or receptor binding assays for this compound typically involve studies with purified enzymes or receptors to evaluate the effects of N-methylation on binding affinity and enzymatic activity. Standard protocols include incubating varying concentrations of the test compound with the target protein in appropriate buffer systems, followed by measurement of binding or enzymatic activity using spectrophotometric, fluorometric, or surface plasmon resonance (SPR) methods. For peptide synthesis applications, the compound is evaluated in coupling reactions using standard carbodiimide-mediated chemistry to assess reactivity and coupling efficiency. The Fmoc protecting group allows for selective deprotection under mild basic conditions (e.g., piperidine), while the OtBu group can be removed under acidic conditions.
|
| Cell Assay |
Cell-based assays for this N-methylated aspartic acid derivative typically utilize mammalian cell lines, particularly immune cells such as lymphocytes, to evaluate compound effects on cell proliferation and cytokine production. Standard protocols involve culturing cells in appropriate media at 37°C in 5% CO₂, followed by treatment with varying concentrations of the compound (typically 0.1-100 μM) for 24-72 hours. Cell proliferation is assessed using MTT or thymidine incorporation assays. Cytokine release is measured using ELISA or multiplex bead-based assays. For peptide synthesis applications, the compound is used as a building block in solid-phase peptide synthesis (SPPS) protocols.
|
| Animal Protocol |
In vivo animal studies for immunosuppressive agents typically involve administration via oral gavage, intraperitoneal injection, or intravenous injection in rodent models (mice or rats). Standard protocols include dosing at ranges of 1-50 mg/kg body weight, with observations over 1-14 days depending on the study objectives. For studies evaluating immunosuppressive properties, animals may be administered the compound or peptides containing it and monitored for immune cell populations, cytokine levels, and inflammatory responses. Pharmacodynamic assessments may include blood sampling for immunological analysis, tissue collection for histopathological examination, and monitoring of body weight and general health parameters. All animal studies must comply with institutional ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for this protected amino acid can be inferred from structurally related compounds. As a medium-sized molecule (molecular weight 425.47 g/mol), it is expected to have moderate bioavailability. The Fmoc and OtBu protecting groups are likely to be cleaved in vivo to release the active N-methylaspartic acid. The compound shows moderate solubility in organic solvents such as DMSO and can be formulated for in vitro studies. For in vivo administration, formulations using suitable co-solvent systems may be employed. The compound should be stored as powder at -20°C for long-term preservation. Definitive PK parameters such as half-life, Cmax, and AUC require formal studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for this specific compound are limited as it is supplied for research use only and not intended for human therapeutic applications. The immunosuppressive properties observed in vitro suggest that the compound or its derivatives may modulate immune function, which could have implications for toxicity. Appropriate safety precautions should be observed during handling, including the use of personal protective equipment and work in well-ventilated areas. The compound may cause skin and eye irritation upon contact. Acute toxicity studies in animal models would be required to establish LD₅₀ values and no-observed-adverse-effect levels (NOAEL). For in vitro cytotoxicity assessment, the compound can be tested in mammalian cell lines using standard MTT or LDH release assays.
|
| References | |
| Additional Infomation |
Fmoc-N-Me-Asp(OtBu)-OH is an aspartic acid analogue and Nα-methylated protected amino acid featuring Fmoc, N-methyl, and tert-butyl (OtBu) protecting groups. It is a key building block in Fmoc-based solid-phase peptide synthesis (SPPS). The compound has potential immunosuppressive properties and has been shown to inhibit lymphocyte proliferation and suppress the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα. It is not an approved drug and has not undergone clinical trials; it is strictly for research purposes.
|
| Molecular Formula |
C24H27NO6
|
|---|---|
| Molecular Weight |
425.47
|
| Exact Mass |
425.183
|
| CAS # |
152548-66-8
|
| PubChem CID |
7019716
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
598.7±50.0 °C at 760 mmHg
|
| Melting Point |
135-140°C
|
| Flash Point |
315.9±30.1 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.575
|
| LogP |
5.65
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
31
|
| Complexity |
650
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C(N(C([H])([H])[H])[C@]([H])(C(=O)O[H])C([H])([H])C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C1([H])C2=C([H])C([H])=C([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
CYWWLVIEAOUXGW-FQEVSTJZSA-N
|
| InChi Code |
InChI=1S/C24H27NO6/c1-24(2,3)31-21(26)13-20(22(27)28)25(4)23(29)30-14-19-17-11-7-5-9-15(17)16-10-6-8-12-18(16)19/h5-12,19-20H,13-14H2,1-4H3,(H,27,28)/t20-/m0/s1
|
| Chemical Name |
(2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3503 mL | 11.7517 mL | 23.5034 mL | |
| 5 mM | 0.4701 mL | 2.3503 mL | 4.7007 mL | |
| 10 mM | 0.2350 mL | 1.1752 mL | 2.3503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
